NCT05888493 2026-03-24
LEDA
Novartis
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT06097364 2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT05578976 2025-01-23
EPCORE DLBCL-2
Genmab
Phase 3 Active not recruiting
NCT00495079 2021-03-05
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02568683 2019-04-17
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Gilead Sciences
Phase 1/2 Terminated
NCT02486952 2016-02-22
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Hoffmann-La Roche
Completed
NCT00441168 2014-03-21
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
Janssen-Cilag International NV
Phase 2 Terminated